TELANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

TELA Bio, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$0.97−0.00 (-0.48%)

Close on Oct 19, 2026

Market cap: $55.71M
P/E (TTM): –
Dividend yield: –

Dividends

TELA Bio has not reported a dividend

No dividend per share appears in TELA Bio's annual filings since fiscal 2016.

Where these numbers come from

Parsed from the XBRL in TELA Bio's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TELA.

Revenue growth6.1% · median 1.0%

Gross margin67.8% · median 77.1%

Operating margin-42.6% · median -46.6%

Net margin-51.5% · median -55.0%

Company	Revenue	Growth
ANIK	$120.65M	+5.3%
XTNT	$109.53M	-14.3%
LUNG	$87.44M	-3.4%
TELA	$79.91M	+6.1%
RCEL	$75.63M	+1.0%
SI	$60.06M	+60.9%

Company

Next earnings (est.): Nov 12, 2026, after close
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 218
Held by institutions: 70.5%
Auditor: KPMG LLP
SEC CIK: 1561921

Advertisement
300 × 250